Last reviewed · How we verify

NCT06066996

Evaluation of the Electronic Cigarette Withdrawal Syndrome

Recruiting now EARLY_PHASE1 Last updated 14 July 2025
What this trial tests

EARLY_PHASE1 trial testing Transdermal Nicotine Patch in E-cigarette Use in 150 participants. Currently enrolling.

Timeline
28 November 2023
Primary endpoint
30 June 2028
30 June 2028

Quick facts

Lead sponsorJohns Hopkins University
PhaseEARLY_PHASE1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposebasic science
Enrollment150
Start date28 November 2023
Primary completion30 June 2028
Estimated completion30 June 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Johns Hopkins University

Who can join

Adults 21 to 55, any sex, with E-cigarette Use or Withdrawal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this project is to rigorously evaluate the nature of e-cigarette withdrawal in exclusive e-cigarette users during a monitored abstinence period and the role of nicotine in the expression of this withdrawal syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transdermal Nicotine Patch

Trials testing the same drug.

Other recruiting trials for E-cigarette Use

Currently open trials in the same condition.

Other Johns Hopkins University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06066996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing